Cargando…

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies

OBJECTIVE: To evaluate sialic acid binding Ig-like lectin 1 (SIGLEC1) expression on monocytes by flow cytometry as a type I interferon biomarker in idiopathic inflammatory myopathies (IIM). METHODS: We performed a retrospective analysis of adult and paediatric patients with the diagnosis of IIM. SIG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Manuel, von Stuckrad, Sae Lim, Uruha, Akinori, Klotsche, Jens, Zorn-Pauly, Lydia, Unterwalder, Nadine, Buttgereit, Thomas, Krusche, Martin, Meisel, Christian, Burmester, Gerd R, Hiepe, Falk, Biesen, Robert, Kallinich, Tilmann, Stenzel, Werner, Schneider, Udo, Rose, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Connective Tissue Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860073/ https://www.ncbi.nlm.nih.gov/pubmed/35177553 http://dx.doi.org/10.1136/rmdopen-2021-001934

Ejemplares similares

SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus
por: von Stuckrad, Sae Lim, et al.
Publicado: (2020)

Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
por: Meyer, Alain, et al.
Publicado: (2019)

Distinct interferon signatures stratify inflammatory and dysimmune myopathies
por: Rigolet, Muriel, et al.
Publicado: (2019)

Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy
por: Ide, Veerle, et al.
Publicado: (2018)

MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis
por: Ukichi, Taro, et al.
Publicado: (2019)

Pulmonary arterial hypertension, a novelty in idiopathic inflammatory myopathies: insights and first experiences with vasoactive therapy
por: Bhansing, Kavish J, et al.
Publicado: (2017)

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report
por: Bottai, Matteo, et al.
Publicado: (2017)

Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
por: Yeoh, Su-Ann, et al.
Publicado: (2022)

Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases
por: Zarbl, Joshua, et al.
Publicado: (2022)

Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey
por: Talarico, Rosaria, et al.
Publicado: (2020)

IgG4-related diseases: state of the art on clinical practice guidelines
por: Iaccarino, Luca, et al.
Publicado: (2019)

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort
por: Truchetet, Marie-Elise, et al.
Publicado: (2022)

EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
por: Seror, Raphaèle, et al.
Publicado: (2015)

Mixed connective tissue disease: state of the art on clinical practice guidelines
por: Chaigne, Benjamin, et al.
Publicado: (2018)

Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort
por: Carvajal Alegria, Guillermo, et al.
Publicado: (2016)

A prediction model for progressive disease in systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2015)

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?
por: Payet, J, et al.
Publicado: (2015)

Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling
por: Meyer, Alain, et al.
Publicado: (2016)

Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients
por: Danion, François, et al.
Publicado: (2017)

Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores
por: van den Hoogen, Lucas L, et al.
Publicado: (2018)

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses
por: Chen, Bo, et al.
Publicado: (2019)

Undifferentiated connective tissue disease: state of the art on clinical practice guidelines
por: Antunes, Margarida, et al.
Publicado: (2019)

Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
por: Cannizzo, Sara, et al.
Publicado: (2018)

Ehlers-Danlos syndromes: state of the art on clinical practice guidelines
por: Sulli, Alberto, et al.
Publicado: (2018)

Clinical practice guidelines: the first year of activity of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET)
por: Mosca, Marta, et al.
Publicado: (2018)

Relapsing polychondritis: state of the art on clinical practice guidelines
por: Rednic, Simona, et al.
Publicado: (2018)

Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines
por: Howard Tripp, Nadia, et al.
Publicado: (2016)

Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults
por: Tektonidou, Maria G, et al.
Publicado: (2019)

Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease
por: Nishina, Naoshi, et al.
Publicado: (2020)

Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study
por: Abisror, Noemie, et al.
Publicado: (2020)

All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019
por: Bournia, Vasiliki-Kalliopi, et al.
Publicado: (2021)

Suitability for e-health of non-pharmacological interventions in connective tissue diseases: scoping review with a descriptive analysis
por: Ritschl, Valentin, et al.
Publicado: (2021)

Understanding the value of non-specific abnormal capillary dilations in presence of Raynaud’s phenomenon: a detailed capillaroscopic analysis
por: Pacini, Greta, et al.
Publicado: (2022)

Pseudoacrocyanosis: a case for telemedicine in rheumatology
por: Manger, Bernhard, et al.
Publicado: (2022)

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023)

Impact of patient ancestry on heterogeneity of Sjögren’s disease
por: Beydon, Maxime, et al.
Publicado: (2023)

Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study
por: Abe, Kazuya, et al.
Publicado: (2023)

Exploring patient’s experience and unmet needs on pregnancy and family planning in rare and complex connective tissue diseases: a narrative medicine approach
por: Marinello, Diana, et al.
Publicado: (2022)

Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort
por: Liem, Sophie I E, et al.
Publicado: (2023)

Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?
por: Panagiotopoulos, Alexandros, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fqir2in6r05hqg94s9ri2ggm0a